Sector News

Drugmaker GSK to eliminate 650 U.S. jobs

September 7, 2018
Life sciences

British drugmaker GlaxoSmithKline Plc said on Wednesday it would cut about 650 positions in the United States related to a global restructuring program it announced in July.

The job cuts would include about 100 each in its back office in Philadelphia and at Research Triangle Park, North Carolina, and 450 sales representatives, GlaxoSmithKline spokeswoman Mary Anne Rhyne said in a statement.

The savings from these cuts will help fund increases in research and development and commercial support of new products, Rhyne said.

GSK employs about 15,000 people in the United States.

By Sathvik N

Source: Reuters

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”